BACKGROUND: A multicomponent meningococcal serogroups ABCWY vaccine (MenABCWY) could provide broad protection against disease-causing meningococcal strains and simplify the immunisation schedule. The aim of this trial was to confirm the effect of the licensed meningococcal serogroup B (MenB) vaccine, 4CMenB, against diverse MenB strains, and to assess the breadth of immune response against a panel of 110 MenB strains for MenABCWY containing the antigenic components of 4CMenB and licensed serogroups ACWY vaccine, MenACWY-CRM, the non-inferiority of the immune response with MenABCWY versus 4CMenB and MenACWY-CRM, safety, and MenABCWY lot-to-lot consistency. METHODS: We conducted a phase 3 randomised, controlled, observer-blinded trial of healthy adolescents and young adults (age 10-25 years) across 114 centres in Australia, Canada, Czechia, Estonia, Finland, Türkiye, and the USA. Exclusion criteria included previous vaccination with a MenB vaccine or (within the last 4 years) MenACWY vaccine. Participants were randomly allocated (5:5:3:3:3:1 ratio) via a central randomisation system using a minimisation procedure to receive 4CMenB at months 0, 2, and 6 (referred to as 4CMenB 0-2-6 hereafter); or 4CMenB at months 0 and 6 (referred to as 4CMenB 0-6 hereafter); or MenABCWY (three groups, each receiving one production lot of the MenACWY-CRM component) at months 0 and 6; or MenACWY-CRM at month 0. Demonstration in the per-protocol set of the consistency of three MenACWY-CRM component lots of the MenABCWY vaccine was a primary objective (demonstrated with two-sided 95% CIs for the ratio of human serum bactericidal antibody [hSBA] geometric mean titres against each serogroup within predefined criteria [0·5-2·0]). The primary endpoints (breadth of immune response) for the MenB component of MenABCWY and 4CMenB were measured using the endogenous complement hSBA (enc-hSBA) assay against a panel of 110 diverse MenB invasive disease strains. For each serum sample, 35 strains from the 110 MenB strain panel were randomly selected for testing. The 4CMenB breadth of immune response data have been published separately. For MenABCWY, breadth of immune response was assessed in two analyses: a test-based analysis of the percentage of samples (tests) without bactericidal serum activity against MenB strains 1 month after two MenABCWY doses versus the percentage after one MenACWY-CRM dose in the per-protocol set, and a responder-based analysis of the percentage of participants (responders) whose sera killed 70% or more strains at 1 month after two MenABCWY doses in the full analysis set. A lower limit of two-sided 95% CI above 65% would demonstrate breadth of immune response. Other primary outcomes included non-inferiority (5% margin) of two MenABCWY doses versus two 4CMenB doses by enc-hSBA assay in the per-protocol set, non-inferiority (10% margin) of two MenABCWY doses versus one MenACWY-CRM dose in MenACWY vaccine-naive participants by traditional hSBA assay in the per-protocol set, and safety in all vaccinated participants. This trial is registered with ClinicalTrials.gov, NCT04502693, and is complete. FINDINGS: Between Aug 14, 2020, and Sept 3, 2021, 3651 participants were enrolled and randomly allocated (900 in the 4CMenB 0-2-6 group and 908 in the 4CMenB 0-6 group, 1666 in the three MenABCWY groups combined, and 177 in the MenACWY-CRM group). All primary objectives for MenABCWY were met. Consistency of immune responses against the three production lots of the MenACWY component of MenABCWY was demonstrated since two-sided 95% CIs for the ratios of hSBA geometric mean titres against serogroups A, C, W, and Y for each pair of lots were within the predefined equivalence criteria. The lot data were pooled for the remainder of MenABCWY endpoints. By enc-hSBA assay, breadth of immune response against the MenB strain panel was 77·9% (95% CI 76·6 to 79·2) in the test-based analysis and 84·1% (81·4 to 86·5; 687 of 817 participants) in the responder-based analysis. Non-inferiority of MenABCWY to 4CMenB was demonstrated by enc-hSBA assay: the difference in percentage of samples with bactericidal serum activity between the MenABCWY group (82·5% [95% CI 82·1 to 83·0]; 21 222 of 25 715) and 4CMenB 0-2 group (83·1% [82·7 to 83·6]; 22 921 of 27 569) was -0·61% (-1·25 to 0·03). Non-inferiority of two-dose MenABCWY to one-dose MenACWY-CRM was demonstrated by traditional hSBA assay, with differences between the MenABCWY group and MenACWY group in percentages of participants with a four-fold rise in hSBA titres of 11·3% (5·9 to 19·0) for serogroup A, 47·2% (38·1 to 56·3) for serogroup C, 35·3% (26·9 to 44·5) for serogroup W, and 27·0% (19·4 to 35·8) for serogroup Y. MenABCWY reactogenicity was mostly of mild or moderate severity and transient, with similar frequencies of adverse events in the MenABCWY and 4CMenB groups and no safety concerns were identified. INTERPRETATION: This study demonstrates breadth of immune response against a panel of 110 MenB strains for the MenB component of the investigational MenABCWY vaccine, when administered as a 0-6 months schedule to the target population of adolescents and young adults, with predefined criteria for success met for both breadth of immune response endpoints and for non-inferiority versus 4CMenB. This investigational vaccine could provide broad meningococcal serogroup coverage in a simplified immunisation schedule, thus aiding the public health attempt in preventing invasive meningococcal disease due to five Neisseria meningitidis serogroups in adolescents and young adults. FUNDING: GSK.
- MeSH
- Child MeSH
- Adult MeSH
- Immunogenicity, Vaccine * MeSH
- Single-Blind Method MeSH
- Humans MeSH
- Meningococcal Infections * prevention & control immunology MeSH
- Meningococcal Vaccines * immunology adverse effects administration & dosage MeSH
- Adolescent MeSH
- Young Adult MeSH
- Neisseria meningitidis, Serogroup B immunology MeSH
- Neisseria meningitidis immunology MeSH
- Antibodies, Bacterial blood MeSH
- Healthy Volunteers MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Equivalence Trial MeSH
- Clinical Trial, Phase III MeSH
- Multicenter Study MeSH
OBJECTIVES: To prospectively validate the diagnostic performance of a non-invasive point-of-care tool (Rapid IAI System), including vaginal alpha-fetoprotein and interleukin-6, to predict the occurrence of intra-amniotic inflammation in a Spanish cohort of patients admitted with a diagnosis of preterm labor and intact membranes. METHODS: From 2017 to 2022, we prospectively evaluated a cohort of pregnant women diagnosed with preterm labor and intact membranes admitted below 34+0 weeks who underwent amniocentesis to rule-in/out intra-amniotic infection and/or inflammation. Vaginal sampling was performed at the time of amniocentesis or within 24-48 h. Amniotic fluid IL-6, vaginal alpha-fetoprotein and vaginal IL-6 concentrations were measured using a point-of-care tool provided by Hologic Inc., "Rapid IAI System". We defined intra-amniotic inflammation when amniotic fluid IL-6 values were greater than 11.3 ng/mL. During recruitment, clinicians were blinded to the results of the point-of-care tool. The original prediction model proposed by Hologic Inc. to predict intra-amniotic inflammation was validated in this cohort of patients. RESULTS: We included 151 patients diagnosed with preterm labor and intact membranes. Among these, 29 (19.2 %) had intra-amniotic inflammation. The algorithm including vaginal IL-6 and alpha-fetoprotein showed an area under curve to predict intra-amniotic inflammation of 80.3 % (±5.3 %) with a sensitivity of 72.4 %, specificity of 84.6 %, positive predictive valuve (PPV) of 52.5 %, negative predictive value (NPV) of 92.9 %, and a positive likelihood ratio (LR+) of 4.6 and negative likelihood ratio (LR-) of 0.33. CONCLUSIONS: External validation of a non-invasive rapid point-of-care tool, including vaginal alpha-fetoprotein and IL-6, showed very good diagnostic performance for predicting the absence of intra-amniotic inflammation in women with preterm labor and intact membranes.
- MeSH
- alpha-Fetoproteins * analysis metabolism MeSH
- Amniocentesis methods MeSH
- Chorioamnionitis * diagnosis MeSH
- Adult MeSH
- Risk Assessment methods MeSH
- Interleukin-6 * analysis blood metabolism MeSH
- Humans MeSH
- Amniotic Fluid * metabolism chemistry MeSH
- Point-of-Care Testing MeSH
- Obstetric Labor, Premature * diagnosis MeSH
- Predictive Value of Tests MeSH
- Prospective Studies MeSH
- Pregnancy MeSH
- Vagina metabolism MeSH
- Point-of-Care Systems MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Validation Study MeSH
BACKGROUND: Emerging evidence suggests that tumour morphological heterogeneity may influence mutational profiles relevant to therapy response. In this pilot study, we aimed to assess whether mutations identified within specific morphological patterns or at the invasion front correlate with shorter time to progression after anti-EGFR therapy, as compared to whole-tissue analysis. METHODS: We investigated genetic mutations in 142 samples from primary tumours of 39 KRAS wild-type metastatic colorectal cancer (CRC) patients receiving anti-EGFR therapy. Deep next-generation sequencing was performed on whole-tumour sections and six morphology-defined tumour regions. RESULTS: Mutations in genes linked to anti-EGFR therapy response (KRAS, BRAF, NRAS, PTEN and PI3KCA) were found uniquely in the non-responder group, with substantial variability across morphological sub-regions. BRAF mutations were aligned with serrated and mucinous morphologies, while KRAS mutations (p.Lys147Glu and p.Ala146Thr) were associated with mucinous and desmoplastic morphologies. In all cases, the cumulative mutational profile from sub-regions provided more details than that of the whole-tumour profile. CONCLUSION: Our findings highlight that comprehensive analysis, considering morphological heterogeneity, is crucial for personalised CRC treatment strategies.
- MeSH
- Drug Resistance, Neoplasm * genetics MeSH
- Adult MeSH
- ErbB Receptors antagonists & inhibitors MeSH
- PTEN Phosphohydrolase genetics MeSH
- GTP Phosphohydrolases genetics MeSH
- Protein Kinase Inhibitors * therapeutic use MeSH
- Colorectal Neoplasms * genetics drug therapy pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Mutation * MeSH
- DNA Mutational Analysis MeSH
- Pilot Projects MeSH
- Antineoplastic Agents * therapeutic use MeSH
- Proto-Oncogene Proteins B-raf genetics MeSH
- Proto-Oncogene Proteins p21(ras) genetics MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- High-Throughput Nucleotide Sequencing MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
INTRODUCTION: The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) may be as high as 38% in the adult population with potential serious complications, multiple comorbidities and a high socioeconomic burden. However, there is a general lack of awareness and knowledge about MASLD and its progressive stages (metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis). Therefore, MASLD is still far underdiagnosed. The 'Global Research Initiative for Patient Screening on MASH' (GRIPonMASH) consortium focuses on this unmet public health need. GRIPonMASH will help (primary) healthcare providers to implement a patient care pathway, as recommended by multiple scientific societies, to identify patients at risk of severe MASLD and to raise awareness. Furthermore, GRIPonMASH will contribute to a better understanding of the pathophysiology of MASLD and improved identification of diagnostic and prognostic markers to detect individuals at risk. METHODS: This is a prospective multicentre observational study in which 10 000 high-risk patients (type 2 diabetes mellitus, obesity, metabolic syndrome or hypertension) will be screened in 10 European countries using at least two non-invasive tests (Fibrosis-4 index and FibroScan). Blood samples and liver biopsy material will be collected and biobanked, and multiomics analyses will be conducted. ETHICS AND DISSEMINATION: The study will be conducted in compliance with this protocol and applicable national and international regulatory requirements. The study initiation package is submitted at the local level. The study protocol has been approved by local medical ethical committees in all 10 participating countries. Results will be made public and published in scientific, peer-reviewed, international journals and at international conferences. REGISTRATION DETAILS: NCT05651724, registration date: 15 Dec 2022.
- MeSH
- Diabetes Mellitus, Type 2 complications MeSH
- Liver Cirrhosis diagnosis MeSH
- Humans MeSH
- Metabolic Syndrome complications MeSH
- Multicenter Studies as Topic MeSH
- Non-alcoholic Fatty Liver Disease * diagnosis MeSH
- Mass Screening * methods MeSH
- Prospective Studies MeSH
- Research Design MeSH
- Fatty Liver * diagnosis epidemiology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial Protocol MeSH
Epilepsy, affecting over 50 million people globally, presents a significant neurological challenge. Effective prevention of epileptic seizures relies on proper administration and monitoring of Anti-Seizure Medication (ASMs). Therapeutic Drug Monitoring (TDM) ensures optimal dosage adjustment, minimizing adverse effects and potential drug interactions. While traditional venous blood collection for TDM may be stressful, emerging alternative sampling methods, particularly Dried Blood Spot (DBS) or oral fluid offer less invasive way of sampling. This study aimed to develop and validate an analytical method for the determination of lamotrigine in such alternative samples. The sample, either DBS or oral fluid, was subjected to extraction, evaporation, and reconstitution in 15 % acetonitrile containing 0.1 % formic acid. A Kinetex C18 Polar column was used for liquid chromatographic separation and MS in ESI+ mode was used for detection and quantitation of lamotrigine using an isotopically labelled internal standard according to EMA guidelines. The calibration range of the developed method enables the determination of lamotrigine in the concentration range of 1-30 μg/mL in DBS and 0.5-20 μg/mL in oral fluid. Oral fluid and DBS samples from patients treated with lamotrigine analysed by the developed method were compared to plasma concentrations measured by the hospital's accredited laboratory. Preliminary results indicate a promising potential for these alternative matrices in clinical TDM applications. By offering a less invasive sampling approach, this method improves the accessibility and safety of pharmacotherapy for epilepsy patients. The results of this study lay the foundation for further clinical applications by implementing alternative matrix TDM, which may significantly advance personalized care in epilepsy management.
- MeSH
- Anticonvulsants * analysis blood MeSH
- Chromatography, Liquid methods MeSH
- Epilepsy drug therapy MeSH
- Calibration MeSH
- Liquid Chromatography-Mass Spectrometry MeSH
- Lamotrigine * analysis blood MeSH
- Humans MeSH
- Limit of Detection MeSH
- Drug Monitoring * methods MeSH
- Reproducibility of Results MeSH
- Saliva * chemistry MeSH
- Tandem Mass Spectrometry methods MeSH
- Dried Blood Spot Testing * methods MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Validation Study MeSH
Rentgenová výpočetní mikrotomografie (mikroCT) představuje moderní zobrazovací technologii s vysokým rozlišením umožňující detailní analýzu zobrazovaného vzorku. Nabízí jedinečný pohled na trojrozměrnou architekturu díky rozlišení na pomezí makroskopického a histologického zobrazení. V oblasti anatomické patologie mikroCT nachází uplatnění zejména při morfometrické analýze nádorů, hodnocení resekčních okrajů chirurgických vzorků či detekci metastáz v lymfatických uzlinách. Kombinace mikroCT s tradičními histopatologickými technikami a s využitím digitální 3D rekonstrukce otevírá nové možnosti při analýze komplexních patologických procesů. Přestože je tato metoda zatím převážně využívána ve výzkumu, její klinický potenciál je značný. Mezi hlavní přednosti patří neinvazivní zobrazení a možnost integrace s digitální patologií a nástroji umělé inteligence. Hlavními limitacemi v současné době zůstávají potřeba kontrastování vzorků, monochromatická povaha obrazu a vysoká radiační zátěž. Pokrok v technologickém vývoji však může tyto překážky překonat a umožnit širší využití mikroCT v rutinní klinické diagnostice. Tento článek představuje technologii mikroCT a její diagnostický potenciál v patologii, přibližuje její aplikace, výhody a omezení, a nabízí vhled do budoucí perspektivy jejího využití.
X-ray microtomography (microCT) represents a modern high-resolution imaging technology enabling detailed analysis of the tissue. It offers a unique perspective on three-dimensional architecture, bridging the gap between macroscopic and histological imaging. In anatomical pathology, microCT is particularly utilized for morphometric tumor analysis, evaluation of surgical specimen resection margins, and detection of metastases in lymph nodes. The combination of microCT with traditional histopathological techniques, and with digital 3D reconstructions, opens new avenues for analyzing complex pathological processes. Although this method is currently used in research, its clinical potential is significant. Key advantages include non-invasive imaging and the ability to be integrated with digital pathology and artificial intelligence tools. Current limitations include the need for sample contrast enhancement, the monochromatic nature of the images, and high radiation exposure. Advances in technological development, however, may overcome these barriers and enable the broader adoption of microCT in routine clinical diagnostics. This article explores the diagnostic potential of microCT in pathology, highlighting its applications, advantages, and limitations, while offering insights into current capabilities and future perspectives of this technology.
No study has systematically compared the suitability of DNA methylation (DNAme) profiles in non-invasive samples for the detection of breast cancer (BC). We assess non-tumour DNAme in 1,100 cervical, buccal, and blood samples from BC cases and controls and find that cervical samples exhibit the largest nuber of differentially methylated sites, followed by buccal samples. No sites were significant in blood after FDR adjustment. Deriving DNAme-based classifiers for BC detection in each sample type (WID-buccal-, cervical-, or blood-BC), we achieve validation AUCs of 0.75, 0.66, and 0.51, respectively. Buccal and cervical BC-associated DNAme alterations distinguish between BC cases and controls in both surrogate and breast tissue (AUC > 0.88), yet individual sites and the directionality of methylation changes are not identical between these two sample types, and buccal sample DNAme aligns with breast methylation changes more closely. Pending additional validation, these insights may have the potential to improve non-invasive personalized BC prevention.
- MeSH
- Adult MeSH
- Epigenesis, Genetic * MeSH
- Epigenomics * methods MeSH
- Middle Aged MeSH
- Humans MeSH
- DNA Methylation * MeSH
- Breast Neoplasms * genetics diagnosis MeSH
- Case-Control Studies MeSH
- Mouth Mucosa metabolism MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Úvod: Zduření v oblasti hlavy a krku je častým nálezem v otorinolaryngologii. Jeho přesná a časná diagnostika je předpokladem úspěšné léčby, především v případě zhoubných nádorů. Běžně je tenkojehlová aspirační biopsie (FNAB – fine-needle aspiration biopsy) zatížena vysokým počtem nediagnostických vzorků, zatímco otevřená biopsie představuje výkon s vyšším rizikem komplikací a nezřídka nutností hospitalizace. Biopsie tlustou jehlou (CNB – core-needle biopsy) představuje nejméně invazivní metodu k získání tkáně k histologickému vyšetření. Materiál a metodika: V retrospektivní studii bylo hodnoceno celkem 70 CNB u 62 pacientů v období 6/2020–12/2022 s cílem stanovit senzitivitu a specificitu CNB při diagnostice neoplazií v oblasti hlavy a krku. Všechny CNB v souboru byly provedeny otorinolaryngologem. Výsledky: V celém souboru jsme dosáhli senzitivity a specificity ve stanovení neoplazie 69,5 % a 90,9 %. Pro maligní nádor tyto hodnoty činily 53,9 %, resp. 100 %. V případě spinocelulárního karcinomu byla senzitivita 83,3 % a specificita 100 % Pro diagnózu lymfomu jsme dosáhli hodnot 33,3 % pro senzitivitu a 100 % pro specificitu. V oblasti slinných žláz byla neoplazie pomocí CNB diagnostikována se senzitivitou 74,3 % a specificitou 87,5 %. Zaznamenali jsme jedinou komplikaci v podobě krátkodobé dysfunkce lícního nervu. Závěr: Námi dosažené výsledky ukazují na potenciál CNB v diagnostice nádorů v oblasti hlavy a krku. V případě stanovení diagnózy spinocelulárního karcinomu dosahuje vysoké specificity, zatímco u lymfomů ji limituje nízká senzitivita. Ultrazvuková navigace je výhodou především u malých a špatně hmatných lézí.
Introduction: A neck lump is a common finding in ENT practice. Its early and precise diagnostics are the corner stone for successful treatment, especially in cases of malignant tumours. Commonly used fine-needle aspiration biopsy has a high rate of non-diagnostic results, while open surgical biopsy poses a procedure with a higher incidence of complications and the necessity of hospital admission. Core-needle biopsy (CNB) represents the least invasive method of obtaining a tissue sample sufficient for histological examination. Methods: In our retrospective study, we investigated 70 CNBs taken from 62 patients between 6/2020 to 12/2022. The outcome measures were the sensitivity and specificity of CNB in diagnosing neoplasia of the head and neck. All CNBs were performed by an otorhinolaryngologist. Results: In the entire cohort, the sensitivity and specificity for neoplasia were 69.5% and 90.9%, respectively. For malignancy, the sensitivity was 53.9% and the specificity was 100%. In cases of squamous cell carcinoma, we reached 83.3% for sensitivity and 100% for specificity. For lymphoma, the sensitivity and specificity were 33.3% and 100%, respectively. CNB sensitivity and specificity for salivary neoplasia were 74. % and 87.5%, respectively. We encoutered a single complication, i.e. temporary paresis of the facial nerve, which resolved spontaneously soon afterwards. Conclusion: Our results underline the potential of CNB in diagnosing head and neck neoplasias. It is highly specific for squamous cell carcinoma, while it lacks sufficient sensitivity for lymphomas. Ultrasound guidance is recommended especially for small and impalpable lessions.
- Keywords
- biopsie tlustou jehlou,
- MeSH
- Biopsy methods MeSH
- Humans MeSH
- Head and Neck Neoplasms * diagnosis MeSH
- Retrospective Studies MeSH
- Check Tag
- Humans MeSH
BACKGROUND: To validate the clinical utility of a previously identified circulating tumor DNA methylation marker (meth-ctDNA) panel for disease detection and survival outcomes, meth-ctDNA markers were compared to PSA levels and PSMA PET/CT findings in men with different stages of prostate cancer (PCa). METHODS: 122 PCa patients who underwent [68Ga]Ga-PSMA-11 PET/CT and plasma sampling (03/2019-08/2021) were analyzed. cfDNA was extracted, and a panel of 8 individual meth-ctDNA markers was queried. PET scans were qualitatively and quantitatively assessed. PSA and meth-ctDNA markers were compared to PET findings, and their relative prognostic value was evaluated. RESULTS: PSA discriminated best between negative and tumor-indicative PET scans in all (AUC 0.77) and hormone-sensitive (hsPC) patients (0.737). In castration-resistant PCa (CRPC), the meth-ctDNA marker KLF8 performed best (AUC 0.824). CHST11 differentiated best between non- and metastatic scans (AUC 0.705) overall, KLF8 best in hsPC and CRPC (AUC 0.662, 0.85). Several meth-ctDNA markers correlated low to moderate with the tumor volume in all (5/8) and CRPC patients (6/8), while PSA levels correlated moderately to strongly with the tumor volume in all groups (all p < 0.001). CRPC overall survival was independently associated with LDAH and PSA (p = 0.0168, p < 0.001). CONCLUSION: The studied meth-ctDNA markers are promising for the minimally-invasive detection and prognostication of CRPC but do not allow for clinical characterization of hsPC. Prospective studies are warranted for their use in therapy response and outcome prediction in CRPC and potential incremental value for PCa monitoring in PSA-low settings.
- MeSH
- Circulating Tumor DNA genetics blood MeSH
- Edetic Acid analogs & derivatives MeSH
- Gallium Isotopes * MeSH
- Middle Aged MeSH
- Humans MeSH
- DNA Methylation * genetics MeSH
- Biomarkers, Tumor * genetics blood MeSH
- Prostatic Neoplasms, Castration-Resistant genetics blood diagnostic imaging MeSH
- Prostatic Neoplasms * genetics blood diagnostic imaging MeSH
- Positron Emission Tomography Computed Tomography * methods MeSH
- Prognosis MeSH
- Prostate-Specific Antigen * blood genetics MeSH
- Cross-Sectional Studies MeSH
- Gallium Radioisotopes * MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
Depression is associated with a significant burden on individuals, families, and communities. It leads to impaired social and occupational functioning, increased disability, decreased quality of life, and higher mortality rates, often due to suicide. A recent estimate from the World Health Organization (WHO) states that over 280 million people of all ages suffer from depression, which equals approximately 3.8% of the world population. Despite effective treatments for mental disorders, a dire treatment gap persists. This treatment gap could be reduced by effective and available diagnostic methods that have the potential to aid in depression diagnosis, stratification of patient subgroups, and treatment monitoring. In this regard, salivary hormones have been studied as potential markers for different types and etiologies of depression due to the convenience of non-invasive sample collection and their correlation with certain aspects of mood and mental health. The literature suggests they can help clinicians assess an individual's stress response, hormonal imbalances, and treatment response, leading to more personalized and effective interventions. In this review, we offer an up-to-date look at all studied salivary hormones associated with depression, including Cortisol, Melatonin, Oxytocin, Serotonin, Dehydroepiandrosterone, Testosterone, Progesterone, and Estradiol.
- Publication type
- Journal Article MeSH
- Review MeSH
